Annelies H. Boekhout

Annelies H. Boekhout

Auto-generated profile, based on publicly available information

Annelies H. Boekhout

Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2015 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
FIfor the FUPII Trial Investigators
for the FUPII Trial Investigators
ABAnnelies H. Boekhout
Annelies H. Boekhout
EMElizabeth Maunsell
Elizabeth Maunsell
GPGregory R. Pond
Gregory R. Pond
JJJim A. Julian
Jim A. Julian
EGEva Grunfeld
Eva Grunfeld

1 June 2006 in The Oncologist
Verified
Journal Article
Closed access
PDF file
ABAnnelies H. Boekhout
Annelies H. Boekhout
JBJos H. Beijnen
Jos H. Beijnen
JSJan H.M. Schellens
Jan H.M. Schellens
Learning Objectives: After completing this course, the reader will be able to: Describe the therapeutic options when hot flashes disrupt the quality of life or quality of sleep in breast cancer patients.Select appropriate nonpharmacological or pharmacological options in the management of hot flashes in breast cancer patients.Discuss the relative efficacy and safety of interventions in the treatment of hot flashes in breast cancer patients. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com

14 September 2020 in Acta Oncologica
Verified
Journal Article
Open access
ABA. H. Boekhout
A. H. Boekhout
ARA. Rogiers
A. Rogiers
KJK. Jozwiak
K. Jozwiak
MBM. J. Boers-Sonderen
M. J. Boers-Sonderen
AEA. J. van Den Eertwegh
A. J. van Den Eertwegh
CBC. U. Blank
C. U. Blank
Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma su...

19 May 2022 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
IFItske Fraterman
Itske Fraterman
SGSavannah L. C. Glaser
Savannah L. C. Glaser
SWSofie Wilgenhof
Sofie Wilgenhof
SMStephanie K. Medlock
Stephanie K. Medlock
HMHenk A. Mallo
Henk A. Mallo
ABAnnelies H. Boekhout
Annelies H. Boekhout

1 February 2023 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
MEMees D. Egeler
Mees D. Egeler
MLMarieke van Leeuwen
Marieke van Leeuwen
IFItske Fraterman
Itske Fraterman
NHNoelle M.J. van Den Heuvel
Noelle M.J. van Den Heuvel
ABAnnelies H. Boekhout
Annelies H. Boekhout
LPLonneke V. van de Poll-Franse
Lonneke V. van de Poll-Franse
This systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma. OVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included. Toxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation. The toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.

1 September 2021 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
JKJacobien M Kieffer
Jacobien M Kieffer
DSDanielle Elizabeth Jacoba Starreveld
Danielle Elizabeth Jacoba Starreveld
ABAnnelies Boekhout
Annelies Boekhout
EBEvelline M.A. Bleiker
Evelline M.A. Bleiker
One of the most commonly used tools to measure fatigue is the Multidimensional Fatigue Inventory (MFI). Studies into the scale structure of the MFI show discrepant findings. The objective of this study was to investigate the scale structure of the MFI in the general Dutch population. Using data from a Dutch probability-based internet panel (n = 2512), the original 5-factor model, a 4-factor, and a 5- and 4-bifactor model of the MFI were tested with confirmatory factor analyses. Additional models were investigated using exploratory factor analysis. Results neither confirmed a 5-factor (RMSEA = 0.120, CFI = 0.933, TLI = 0.920) nor a 4-factor model (RMSEA = 0.122, CFI = 0.928, TLI = 0.917). The two bi-factor models also showed a poor fit (bi-4-factor: RMSEA = 0.151, CFI = 0.895, TLI = 0.873; bi-5-factor: RMSEA = 0.153, CFI = 0.894, TLI = 0.871). Exploratory factor analysis did not support an alternative model, but seemed to show robustness in the loading of the original general fatigue items. Our results did not provide empirical support for a four or five (bi-)factor structure of the MFI, nor for an alternative model. The most reliable scale of the MFI seems to be the general fatigue scale that could be used as a general indicator of fatigue.